Gabify, a healthtech startup, has raised $175,000 in pre-seed funding led by Inflection Point Ventures (IPV). The company said it has received ₹25 lakhs under the Nidhi Seed Support Scheme from GHRTBI, the G H Raisoni Technology Business Incubator Foundation, a government-backed incubator.
The startup says its platform is designed for early screening and therapy support in conditions such as autism and ADHD, areas where diagnosis and intervention are often delayed. In the company’s own framing, the goal is to reduce the time clinicians spend on assessments while keeping clinical accuracy intact.
Gabify says its system uses a dual-AI approach combining voice and vision to capture more than speech alone. The platform analyzes speech patterns along with facial expressions, eye gaze, and behavior, and the company says it does so using 189-plus clinically validated criteria aligned with DSM-5 and CARS. The product is built with a human-in-the-loop model, meaning clinical outputs are reviewed by professionals before they are used in care decisions. That structure is important in healthtech because it places AI in an assistive role rather than a fully autonomous one.
According to the company, the platform is multilingual, low-bandwidth, and suited to rural communities, which could matter in a market where access to specialists remains uneven. The company said the model was designed for Bharat but could also scale globally because of its software architecture and workflow design.
Gabify said its services were tested in more than 35 preschool and daycare centres across India during private beta. It added that schools, hospitals, private practices, and non-profits have already begun using the platform. For a company at pre-seed stage, that kind of early field testing matters more than product claims because it shows where the tool has actually been used rather than simply demonstrated.
The company said its technology can reduce assessment time by up to 70%, which would let clinicians handle more patients without lowering quality, according to the release. It also said the platform is part of a broader rollout plan that includes B2B, B2C, and CSR-focused deployments, with a target of reaching 1 million children by 2028. Those figures are company targets, not independently verified outcomes, but they show the scale of the ambition behind the fundraiser.
On the investor side, IPV said the problem Gabify is addressing is underserved and clinically important. In its comment, the firm pointed to the need for earlier detection of neurodevelopmental issues and faster intervention pathways. The company’s backing fits a wider pattern in Indian healthtech, where investors are increasingly looking at AI systems that can improve access, shorten delays, and support clinicians rather than replace them.
Gabify was founded by Sahil Chopra, who has more than 12 years of startup experience, Prachi Sood, a senior speech therapist with more than a decade of clinical practice, and Vasyl Leshchuk, a technology executive with experience in AI, cybersecurity, and large-scale systems.
